FDA Accepts Supplemental NDA for JASCAYD by Boehringer Ingelheim
The FDA has accepted the supplemental NDA for JASCAYD (nerandomilast) submitted by Boehringer Ingelheim.
Asset / Drug
Drug and asset intelligence for JASCAYD with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.